EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

Contributed by: PR Newswire

Tags

EADV

More Like This

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

GlobeNewswire associated0

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress